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Background: Crohn’s disease is a relapsing, systemic inflammatory disease affecting the gastrointestinal tract with
associated extraintestinal manifestations and immune disorders. Among the few cases reported, the association of
Crohn’s disease with polymyositis varies in its complexity and severity. We report here the first known case of
inflammatory polymyositis leading to rhabdomyolysis in a male patient diagnosed with Crohn’s ileocolitis.
Case presentation: A 42-year-old previously healthy man presented with acute polymyositis leading to rhabdomyolysis.
The acute nature of the illness raised the suspicion of an infective, toxic, or metabolic insult, which was excluded during
further investigations. Prolonged low-grade fever and raised inflammatory markers led to the suspicion of inflammatory
polymyositis, which was confirmed by electromyography and muscle histology. In the absence of an infective cause,
the concurrent association of prolonged diarrhea containing blood and mucous after recovery from an acute phase
of myositis proved a diagnostic challenge. Ileocolonoscopy findings of extensive aphthous ulceration with skip lesions
extending to the terminal ileum, and histology showing polymorph infiltration of the lamina propria, transmural
involvement, and micro abscess formation was suggestive of Crohn’s disease. Sensory motor axonal peripheral
neuropathy, which is another rare association of inflammatory bowel disease, was also present.
Conclusion: An unrecognized genetic predisposition or altered gut permeability causing disruption of the gut immune
barrier triggering an immune response against skeletal muscles may have contributed to this unique association. Both
polymyositis and Crohn’s ileocolitis responded well to corticosteroids and azathioprine, which is supportive of their
immune pathogenesis. Myositis can be considered to be a rare extraintestinal manifestation of Crohn’s disease and can
be used in the differential diagnosis of corticosteroid or hypokalemia-induced myopathy in Crohn’s disease.
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Crohn’s disease (CD) is a relapsing systemic inflammatory
disease that predominantly affects the gastrointestinal
tract. Its association with extraintestinal manifestations
is complex, causing many diagnostic and management
challenges. Seronegative spondyloarthropathies have been
reported in 33% of CD patients [1], while erythema nodo-
sum is more common in CD than pyoderma gangrenosum
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and are more often seen in patients with ulcerative colitis
than CD [3,4]. Primary sclerosing cholangitis, thrombo-
embolic events, and nephrolithiasis are less common asso-
ciations of IBD. Moreover, peripheral neuropathy is not
well characterized in IBD and its incidence varies from 0.9
to 3.6% [5,6]. Chronic idiopathic inflammatory myopathy
(IIM) is also a rare association with CD, with one known
study by Szabo et al. of a female CD patient presenting
with chronic IIM [7].
Few cases have reported an association of polymyositis
with CD, although the occurrence of polymyositis, alopeciaed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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served in a male CD patient in Germany [8], and Hall
documented a case of focal myositis involving the left
gastrocnemius muscle [9]. The timing of the onset of myo-
sitis has been shown to vary widely among patients with
IBD [10-12]. Only a small number of cases of rhabdo-
myolysis in association with CD have been reported, of
which the subclinical presentation is more common than
the acute presentation [13]. Most of these were caused by
hypokalemia associated with severe IBD, and only one case
report describes probable immune pathogenesis [10,14-16].
The study of different disease associations will provide new
insights into the complex pathogenesis of IBD, and expan-
sion of the scope of extraintestinal manifestations will aid
the early diagnosis and management of CD. We herein re-
port the first known case of inflammatory polymyositis
complicated with rhabdomyolysis in a male patient diag-
nosed with CD.Figure 1 Section of muscle biopsy stained with HE. Muscle fibers
show perimiceal inflammation, unequal sizes, and swelling.
Mononuclear infiltrations of inter-fiber areas are seen. There is no
granulomata formation (original magnification × 100).Case presentation
A 42-year-old previously healthy man was admitted to
the emergency department with sudden-onset right
upper limb swelling, pain, and weakness associated with
dysphagia, reduced urine output, red-colored urine, and
melena. He had consumed three pints of alcohol 3 days
prior to this presentation but had no history of travel,
trauma, or illicit drug abuse. He had acidotic breathing
on examination.
A full blood count showed severe anemia, thrombo-
cytopenia, and neutrophil leukocytosis. The inflam-
matory markers, erythrocyte sedimentation rate and
C-reactive protein levels were well above the normal
range, which was suggestive of an inflammatory process.
The full urine report confirmed myoglobulinuria. Creat-
ine kinase levels exceded 50,000 U/L, and serum myo-
globin levels were more than 60,000 ng/mL, which was
suggestive of rhabdomyolysis. Clinical and biochemical
parameters confirmed acute kidney injury (AKI). Aspar-
tate transaminase levels (4,795 U/L, normal range 8–48
U/L) exceeded alanine transaminase (ALT) levels, and
were 100 times the normal level, which explained the
leakage from muscle damage. ALT levels were also 40
times the normal level (2,268 U/l, normal range 7–55
U/L), with associated high activated partial thromboplas-
tin time and prothrombin time indicating simultaneous
liver injury. D-dimer levels were within normal limits
and disseminated intravascular coagulation was ex-
cluded. Arterial and venous Doppler scans of the upper
limbs excluded thrombosis as the cause of severe edema
and revealed marked subcutaneous and soft tissue
edema. Initial diagnosis suggested an acute metabolic,
toxic, or infective insult causing myositis and rhabdo-
myolysis leading to AKI.Toxicology screening of the blood was negative for co-
caine, morphine, cannabinoids, amphetamines, barbitu-
rates, benzodiazepines, and tricyclic antidepressants. The
blood alcohol estimation was negative and no electrolyte
imbalance was detected. Screenings for the antibodies
of infective illnesses with similar clinical presentations,
such as leptospirosis, dengue, and hepatitis, were nega-
tive. Based on the clinical suspicion of an unnoticed
snake bite, the patient was treated with poly anti-snake
venom, which is active against the bites of cobra, com-
mon krait, Sri Lankan krait, and saw-scaled viper. How-
ever, no clinical improvement occurred. Septic screening
was repeatedly negative despite an ongoing low-grade
fever. In the absence of another etiology, the above find-
ings were supportive of an autoimmune origin for the
presentation. Electromyography confirmed generalized
polymyositis with predominant lower limb involvement.
However, anti-nuclear antibody, anti-Jo antibody, and ex-
tractable nuclear antigen profiles were negative. Muscle
biopsy and histology revealed myositis (Figures 1 and 2)
with probable immune pathogenicity.
The patient was started on a daily dose of 0.75 mg/kg
(45 mg) oral prednisolone with 2 mg/kg (120 mg) aza-
thioprine, and regular renal replacement therapy was
carried out together with medical management to sup-
port his renal functions. This was followed by a rapid
clinical response with significant improvement of muscle
weakness. However, he continued to have intermittent
diarrhea with blood and mucous that was initially con-
sidered part of his acute illness, but later raised the sus-
picion of an infective or inflammatory etiology. Based on
his prolonged stay at the intensive care unit and treat-
ment with broad spectrum antibiotics, a healthcare-
associated infection or pseudomembranous colitis was
Figure 2 Section of muscle biopsy stained with HE. Loss of cross
striations, focal disintegration of the sarcoplasm, nuclear vesiculations,
and centralization are suggestive of myositis (original magnification
× 100).
Figure 4 Endoscopic view of the descending colon. Multiple,
irregular, extensive and superficial ulceration of the colonic mucosa
is evident. Normal intervening segments were not seen in this view.
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difficile toxins were negative. Ileocolonoscopy revealed
extensive ileocolonic aphthous ulceration (Figures 3 and
4), and the histology of the ileum and colon was sugges-
tive of Crohn’s ileocolitis (Figures 5 and 6) based on the
European Crohn’s and Colitis Organisation guidelines.
Esophagogastroduodenoscopy showed mild antral gastri-
tis, and no radiological contract studies were performed
because of the presence of AKI. Amoebiasis and intes-
tinal tuberculosis were excluded by parasitic and micro-
biological evaluation of mucosal samples. No other
extraintestinal manifestations were found, with the ex-
ception of sensory motor axonal peripheral neuropathy,Figure 3 Endoscopic view of the ascending colon. The mucosal
features of a colon with a cobblestone appearance and surrounding
erythema are supportive of a diagnosis of colonic CD.which was confirmed by nerve conduction studies. Sero-
logical studies evaluating perinuclear anti-neutrophil
cytoplasmic and anti-saccharomyces cerevisiae antibodies
were negative.
Once the diagnosis of inflammatory polymyositis and
CD was established, prednisolone and azathioprine doses
were increased to 1 mg/kg (60 mg) daily and 2.5 mg/kg
(150 mg), respectively, as the bowel symptoms of the pa-
tient continued while on therapy for myositis. Mesacol®
(mesalamine), 400 mg daily, and the probiotic Florastor,
250 mg twice daily, were added to the treatment regi-
men at the same time. Metronidazole was not added in
the presence of neuropathy and in the absence of septicFigure 5 Section of ileal mucosal biopsy stained with HE
showing focal surface ulceration. The crypt architecture is
distorted (non-parallel crypts, variable diameters, and crypt
shortening) in conjunction with focal chronic inflammation.
Glandular distortion and branching are also presented, which are
suggestive of CD (original magnification × 100).
Figure 6 Section of sigmoid colonic mucosal biopsy stained with
HE showing dilated vascular spaces in the focally edematous
lamina propria. There is moderate to dense inflammatory cell infiltrate
predominantly composed of lymphocytes and plasma cells with
micro-abscess formation (original magnification × 100).
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both conditions, which was evidenced by the settling of
diarrhea and fever, improvement of muscle strength, and
significant weight gain by the third week of treatment.
Corticosteroid treatment was reduced by 10 mg twice
weekly once the endoscopic remission of CD was con-
firmed. Mesalamine (mesalazine) and Florastor were dis-
continued and the patient was kept on an azathioprine
maintenance dose of 150 mg daily one month after start-
ing treatment. Special attention was given to the patient’s
nutrition as his muscles were affected by both the disease
process and poor nutrition. A gradual improvement of
renal function was followed by an improvement of myo-
sitis, which was attributed to the recovery of acute tubu-
lar necrosis, secondary to heavy myoglobinuria.Conclusions
CD is known to have different immunopathogenic
mechanisms; therefore, although the serum markers
were negative, an autoimmune disorder remained the
most likely possibility in this patient. The observed rapid
response to corticosteroids and immunosuppressants
also favored this hypothesis. However, the concurrent
presentation of two different relapsing inflammatory
disorders in a male patient with no family history is
unusual. Cuoco previously reported significantly in-
creased blood tumor necrosis factor-α and sphingosine
levels caused by enhanced lipopolysaccharide concentra-
tion (p < 0.01) resulting from altered gut permeability
(p < 0.01) causing a reduction in muscle fiber size [16].
We suggest that a similar mechanism contributed to the
development of an immune response against skeletal
muscle in the present case.Myositis is considered a rare extraintestinal manifestation
of CD, but may in fact be a more common occurrence than
is reported in patients with IBD. A suggestion for physicians
to carefully monitor muscle pain and serum creatine kinase
(CK) levels in patients with IBD was previously made by Al-
Kawas [12]. Moreover, myositis should be strongly suspected
in CD patients with muscle weakness and elevated CK levels,
which may help in the early diagnosis and appropriate treat-
ment of CD. Immune-mediated myositis should be consid-
ered as an important differential diagnosis for myopathy
occurring in IBD secondary to hypokalemia or corticosteroid
treatment [17]. In this case, the acute phase of myositis pre-
ceded the symptoms of Crohn’s colitis, revealing it to be a
separate entity with an inflammatory origin compared with
hypokalemia or corticosteroid-induced myopathy.
The immune-mediated pathogenesis of both conditions
contributed to their rapid remission following immunosup-
pressant treatment in our patient. Another study showed that
when myositis in CD is immune mediated, the treatment of
bowel inflammation should be emphasized as opposed to
corticosteroid or other immunosuppressive therapy [10]. In
this case, complete recovery of both myositis and CD was
achieved with a combination of prednisolone, azathioprine,
and mesalamine treatment. The specific effect of mesalamine
in this patient cannot be assessed as it was added while
increasing the doses of prednisolone and azathioprine.
Myositis and CD together cause profound effects on muscle
biology because of their immune-mediateddamage, and nutri-
tional and metabolic deficiencies. Therefore, overall patient
management should give equal emphasis to achieving remis-
sion as well as correcting metabolic derangements and nutri-
tion. In addition, hypokalemia should be closely monitored
and corticosteroids should be used cautiously in this unique
association as they can contribute to further muscle injury.
The occurrence of immune polymyositis in CD has a
probable related pathophysiological mechanism. Alter-
ations of bowel mucosal permeability causing disruption
of the gut-immune barrier may have triggered an immune
response against skeletal muscle, which warrants further
investigations. Standard immune modulators used in CD
such as prednisolone and azathioprine are effective first-
line therapies to induce remission in both conditions.
Immune-mediated myositis is an important differential
diagnosis for hypokalemia or corticosteroid-induced myo-
pathy, and muscle biopsy plays an important role in its dif-
ferentiation. This case provides new insights into disease
pathogenesis and useful evidence for the management of
CD associated with immune polymyositis.
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